Evidence map›Paper›PMID 34294895›Full record

ArticleBritish journal of cancer2021

Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach.

Ganesh Radhakrishna, Paula Ghaneh

Abstract readEditorial
In one paragraph

Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ganesh RadhakrishnaConsultant Clinical Oncologist, The Christie Hospital, Manchester, UK. g.radhakrishna@nhs.net.
Paula GhanehProfessor of Surgery, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.

Funding

Cancer Research UK 11883Cancer Research UK 15957Cancer Research UK 16186Cancer Research UK 16812Cancer Research UK 17680Cancer Research UK 8968
6 · The paper itself

Abstract

The treatment paradigm for borderline and locally advanced pancreatic cancer is evolving with an increased shift towards utilising systemic chemotherapy and chemoradiation to potentially facilitate more curative resections. This has been driven by the improved outcomes from the use systemic combination chemotherapy on its own, or sequentially with chemoradiation, resulting in improved resection rates and survival outcomes.

Indexed as

ChemoradiotherapyCombined Modality TherapyDrug TherapyHumansMalePancreatectomyPancreatic NeoplasmsPrecision MedicineSurvival Analysis

Identifiers

PMID34294895
PMCPMC8548340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.